Myasthenia gravis is an immune disease, and one of the characteristics of this disease is that the course of the disease is chronic and prolonged, alternating between remission and deterioration, and most patients can be clinically cured after treatment (i.e., the clinical symptoms and signs of the patient disappear, and the patient can live, study, and work normally as normal people, and stop all drugs used to treat myasthenia gravis). It not only causes great physical pain to the patient, but also brings a great burden to the family and society. The disease has a long course and is difficult to treat, which brings great psychological pressure to the patient, thus affecting the improvement and recovery of the disease. A good psychological state will add to the patient’s incomparable ability to resist the disease, and a strong belief in life can promote early recovery from the disease. Some patients can have a long remission period, but patients with this disease often relapse or aggravate the disease due to mental trauma, various infections in the body, overexertion, endocrine disorders, immune dysfunction, women’s menstrual period and many other factors, therefore, the recurrence of myasthenia gravis symptoms becomes a characteristic of this disease. Only by recognizing this and understanding the triggers of recurring symptoms can we take appropriate preventive measures and active treatment to avoid or reduce the recurrence of myasthenia gravis symptoms. The treatment of myasthenia gravis should be based on the specific symptoms of the patient to take targeted treatment, so as to play the best and most effective treatment effect. Among them are the following specific treatment methods: 1. Non-surgical treatment: (1) Chinese herbal medicine treatment; (2) anticholinesterase drug treatment; (3) hormone treatment. In practice, most patients do not use hormones. Patients who were not previously treated with hormones at the time of consultation are not treated with hormones in principle. Those who have been treated with hormones in preparation for surgery may consider gradually reducing the dosage to the point of adapting to surgical treatment. Those who have undergone surgery, those who do not need surgical treatment and those with more urgent conditions can consider hormone therapy. However, the dosage can be gradually reduced to discontinuation after the condition is stable or clinical symptoms disappear. (4) Gammaglobulin therapy; (5) Plasma replacement therapy; (6) Other immunosuppressive therapy. 2.Surgical treatment: thymus abnormalities are common in patients with myasthenia gravis. About 15% of patients with myasthenia gravis have thymoma in combination, and about 70% of patients with myasthenia gravis have thymic hyperplasia or thymoma and lymphatic follicular hyperplasia. Studies have proven that the thymus is the main site for the production of disease-causing antibodies – acetylcholine receptor antibodies, and the occurrence of this disease is closely related to the thymus. T cells, B cells and myxoid cells in the thymus play an important role in the occurrence of myasthenia gravis. Removal of thymoma or hyperplastic thymus removes the main source of pathogenesis in patients with myasthenia gravis, and it is difficult to achieve the ideal treatment for patients with myasthenia gravis without thymus removal. Therefore, the clinical treatment is based on surgical resection treatment. Traditional surgical treatment is open surgery, which requires a median incision of the sternum and is highly traumatic, with a surgical incision of up to 25 cm.